News

Reykjavík, Iceland — September 2026 — Capretto, an Icelandic life-science company developing novel antimicrobial treatments based on naturally occurring lipids, has reached an important milestone with the submission of its first medical device application for market approval. The application covers an innovative short-term topical use on compromised or superficially damaged skin where microbial imbalance may contribute to discomfort, irritation or delayed recovery. The submission represents an important transition for Capretto from research and product development toward commercialization.

Capretto, in collaboration with StratiCELL and CTMR Department of MTC at Karolinska Institutet, has officially kicked-off the Eurostars funded project, HALT-INFECT at the Blue Lagoon in Iceland.